Immunotherapy in the management of melanoma: current status

References

• SznolMAdvances in the treatment of metastatic melanoma: new immunomodulatory agentsSemin Oncol20123919220322484191
   PubMed Web of Science ®Google Scholar
• BalchCMGershenwaldJESoongSJFinal version of 2009 AJCC melanoma staging and classificationJ Clin Oncol200927366199620619917835
   PubMed Web of Science ®Google Scholar
• HanaiziZvan Zwieten-BootBCalvoGThe European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for Human UseEur J Cancer20114823724222030452
   PubMed Web of Science ®Google Scholar
• FDANotable FY 2011 Approvals2011 http://www.fda.gov/AboutFDA/ReportsManualsForms/Reports/ucm276413.htmAccessed August 14, 2012
   Google Scholar
• EggermontAMRobertCNew drugs in melanoma: it’s a whole new worldEur J Cancer2011472150215721802280
   PubMed Web of Science ®Google Scholar
• RobertCThomasLBondarenkoIIpilimumab plus dacarbazine for previously untreated metastatic melanomaN Engl J Med2011364262517252621639810
   PubMed Web of Science ®Google Scholar
• FinnLMarkovicSNJosephRWTherapy for metastatic melanoma: the past, present, and futureBMC Medicine201210232322385436
   PubMed Web of Science ®Google Scholar
• GilchrestBAEllerMSGellerACYaarMThe pathogenesis of melanoma induced by ultraviolet radiationN Engl J Med1999340171341134810219070
   PubMed Web of Science ®Google Scholar
• WeinstockMAEpidemiology, etiology, and control of melanomaMed Health R I200184723423611482278
   PubMedGoogle Scholar
• GandiniSSeraFCattaruzzaMSMeta-analysis of risk factors for cutaneous melanoma: II. Sun exposureEur J Cancer2005411456015617990
   PubMed Web of Science ®Google Scholar
• SinghSDAjaniUAJohnsonCJAssociation of cutaneous melanoma incidence with area-based socioeconomic indicators-United States, 2004–2006J Am Acad Dermatol201165S58S6822018068
   PubMed Web of Science ®Google Scholar
• GellerACSwetterSMBrooksKDemierreMFYarochALScreening, early detection, and trends for melanoma: current status (2000–2006) and future directionsJ Am Acad Dermatol20075755557217870429
   PubMed Web of Science ®Google Scholar
• SwerdlowAJWeinstockMADo tanning lamps cause melanoma? An epidemiologic assessmentJ Am Acad Dermatol199838189989448211
   PubMed Web of Science ®Google Scholar
• DoreJFChignolMCTanning salons and skin cancerPhotochem Photobiol Sci2012111303721845253
   PubMed Web of Science ®Google Scholar
• International Agency for Research on Cancer Working Group on artificial ultraviolet light and skin cancerThe association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: a systematic reviewInt J Cancer200712051116112217131335
   PubMed Web of Science ®Google Scholar
• LazovichDVogelRIBerwickMWeinstockMAAndersonKEWarshawEMIndoor tanning and risk of melanoma: a case-control study in a highly exposed populationCancer Epidemiol Biomarkers Prev20101961557156820507845
   PubMed Web of Science ®Google Scholar
• HaywardNKGenetics of melanoma predispositionOncogene200322203053306212789280
   PubMed Web of Science ®Google Scholar
• AitkenJWelchJDuffyDCDKN2 A variants in a population-based sample of Queensland families with melanomaJ Natl Cancer Inst199991544645210070944
   PubMedGoogle Scholar
• MosseIKostrovaLSubbotSMaksimenyaIMolopheiVMelanin decreases clastogenic effects of ionizing radiation in human and mouse somatic cells and modifies the radioadaptive responseRadiat Environ Biophys2000391475210789895
   PubMed Web of Science ®Google Scholar
• WachsmuthRCTurnerFBarrettJHThe effect of sun exposure in determining nevus density in UK adolescent twinsJ Invest Dermatol2005124566215654953
   PubMed Web of Science ®Google Scholar
• RiversJKIs there more than one road to melanoma?Lancet2004363941072873015005091
   PubMed Web of Science ®Google Scholar
• GillMCelebiJTB-RAF and melanocytic neoplasiaJ Am Acad Dermatol200553110811415965430
   PubMed Web of Science ®Google Scholar
• EllerhorstJAGreeneVREkmekciogluSClinical correlates of NRAS and BRAF mutations in primary human melanomaClin Cancer Res201117222923520975100
   PubMed Web of Science ®Google Scholar
• CurtinJAFridlyandJKageshitaTDistinct sets of genetic alterations in melanomaN Engl J Med2005353202135214716291983
   PubMed Web of Science ®Google Scholar
• DevittBLiuWSalemiRClinical outcome and pathological features associated with NRAS mutation in cutaneous melanomaPigment Cell Melanoma Res201124466667221615881
   PubMed Web of Science ®Google Scholar
• Edlundh-RoseEEgyhaziSOmholtKNRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencingMelanoma Res20061647147817119447
   PubMed Web of Science ®Google Scholar
• Dal PozzoVBenelliCRoscettiEThe seven features for melanoma: a new dermoscopic algorithm for the diagnosis of malignant melanomaEur J Dermatol19999430330810356410
   PubMed Web of Science ®Google Scholar
• OhsieSJSarantopoulosGPCochranAJBinderSWImmunohistochemical characteristics of melanomaJ Cutan Pathol200835543344418399807
   PubMed Web of Science ®Google Scholar
• GeramiPZembowiczAUpdate on fluorescence in situ hybridization in melanoma: state of the artArch Pathol Lab Med201113583083721732770
   PubMed Web of Science ®Google Scholar
• LinsleyPSNadlerSGThe clinical utility of inhibiting CD28-mediated costimulationImmunol Rev200922930732119426230
   PubMed Web of Science ®Google Scholar
• Bour-JordanHEsenstenJHMartinez-LlordellaMPenarandaCStumpfMBluestoneJAIntrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/B7 familyImmunol Rev2011241118020521488898
   PubMed Web of Science ®Google Scholar
• HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med201036371172320525992
   PubMed Web of Science ®Google Scholar
• ThompsonJAHamidOMinorDIpilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trialJ Immunother2012351737722130164
   PubMed Web of Science ®Google Scholar
• WolchokJDNeynsBLinetteGIpilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging studyLancet Oncol201011215516420004617
   PubMed Web of Science ®Google Scholar
• RibasAHKeffordRPuntCJHaanenJBMarmolMGarbeCPhase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanomaJ Clin Oncol2008209011
   Web of Science ®Google Scholar
• TarhiniAACherianJMoschosSJSafety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanomaJ Clin Oncol201230332232822184371
   PubMed Web of Science ®Google Scholar
• CoxADDerCJRas history: the saga continuesSmall Gtpases20101122721686117
   PubMedGoogle Scholar
• KarasaridesMChiloechesAHaywardRB-RAF is a therapeutic target in melanomaOncogene2004236292629815208680
   PubMed Web of Science ®Google Scholar
• FlahertyKTMcArthurGBRAF, a target in melanoma: implications for solid tumor drug developmentCancer2010116214902491320629085
   PubMed Web of Science ®Google Scholar
• YangHHigginsBKolinskyKRG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma modelsCancer Res201070135518552720551065
   PubMed Web of Science ®Google Scholar
• ChapmanPBHauschildARobertCImproved survival with vemurafenib in melanoma with BRAF V600E mutationN Engl J Med2011364262507251621639808
   PubMed Web of Science ®Google Scholar
• MastrangeloMJBelletREBerkelhammerJClarkWHJrRegression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastasesCancer1975364130513081175129
   PubMed Web of Science ®Google Scholar
• AgarwalaSSNeubergDParkYKirkwoodJMMature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology GroupCancer200410081692169815073858
   PubMed Web of Science ®Google Scholar
• GoodLMMillerMDHighWAIntralesional agents in the management of cutaneous malignancy: a reviewJ Am Acad Dermatol201164241342220334952
   PubMed Web of Science ®Google Scholar
• BedikianAYDel VecchioMAllovectin-7 therapy in metastatic melanomaExpert Opin Biol Ther2008883984418476795
   PubMed Web of Science ®Google Scholar
• NabelGJGordonDBishopDKImmune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexesProc Natl Acad Sci U S A1996932615388153938986821
   PubMed Web of Science ®Google Scholar
• HortonHMDorigoOHernandezPAndersonDBerekJSParkerSEIL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profileJ Immunol1999163126378638510586027
   PubMed Web of Science ®Google Scholar
• BedikianAYRichardsJKharkevitchDAtkinsMBWhitmanEGonzalezRA phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanomaMelanoma Res201020321822620354459
   PubMed Web of Science ®Google Scholar
• LiuBLRobinsonMHanZQICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour propertiesGene Ther20031029230312595888
   PubMed Web of Science ®Google Scholar
• TodaMMartuzaRLRabkinSDTumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factorMol Ther2000232432911020347
   PubMed Web of Science ®Google Scholar
• KaufmanHLKimDWDeRaffeleGMitchamJCoffinRSKim-SchulzeSLocal and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanomaAnn Surg Oncol201017371873019915919
   PubMed Web of Science ®Google Scholar
• KaufmanHLBinesSDOPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanomaFuture Oncol20106694194920528232
   PubMed Web of Science ®Google Scholar
• MousaviHZhangXGillespieSWachterEHerseyPRose bengal induces dual modes of cell death in melanoma cells and has clinical activity against melanomaMelanoma Res200616S8
   Google Scholar
• WachterEDCHarkinsJFisherWScottTImaging photosensitizer distribution and pharmacology using multiphoton microscopyProc SPIE20024622112
   Google Scholar
• ThompsonJFHerseyPWachterEChemoablation of metastatic melanoma using intralesional Rose BengalMelanoma Res200818640541118830132
   PubMed Web of Science ®Google Scholar
• AgarwalaSSTJSmithersBMRossMIChemoablation of metastatic melanoma with rose bengal (PV-10)J Clin Oncol20102815S
   Google Scholar
• KudchadkarRParaisoKHSmalleyKSTargeting mutant BRAF in melanoma: current status and future development of combination therapy strategiesCancer J20121812413122453012
   PubMed Web of Science ®Google Scholar
• NazarianRShiHWangQMelanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationNature201046897397721107323
   PubMed Web of Science ®Google Scholar
• KaiserJCombining targeted drugs to stop resistant tumorsScience201133160241542154521436437
   PubMed Web of Science ®Google Scholar
• MedPage Today [database on the Internet] Available at http://www.medpagetoday.com/PublicHealthPolicy/FDAGeneral/28083Accessed August 21, 2012
   Google Scholar
• MontazeriAQuality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008Health Qual Life Outcomes2009710220030832
   PubMed Web of Science ®Google Scholar
• ButowPNCoatesASDunnSMPsychosocial predictors of survival in metastatic melanomaJ Clin Oncol19991772256226310561283
   PubMed Web of Science ®Google Scholar
• RatajDJankowiakBKrajewska-KulakEQuality-of-life evaluation in an interferon therapy after radical surgery in cutaneous melanoma patientsCancer Nurs20052817217815915059
   PubMed Web of Science ®Google Scholar
• SigurdardottirVBolundCSullivanMQuality of life evaluation by the EORTC questionnaire technique in patients with generalized malignant melanoma on chemotherapyActa Oncol19963521491588639309
   PubMed Web of Science ®Google Scholar
• de VriesMHoekstraHJHoekstra-WeebersJEQuality of life after axillary or groin sentinel lymph node biopsy, with or without completion lymph node dissection, in patients with cutaneous melanomaAnn Surg Oncol200916102840284719639366
   PubMed Web of Science ®Google Scholar
• KahlerKCHauschildATreatment and side effect management of CTLA-4 antibody therapy in metastatic melanomaJ Dtsch Dermatol Ges20119427728621083648
   PubMed Web of Science ®Google Scholar
• ChuEYWanatKAMillerCJDiverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic studyJ Am Acad Dermatol2012126761265127222609219
   PubMed Web of Science ®Google Scholar
• HuangVHepperDAnadkatMCorneliusLCutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathwayArch Dermatol2012148562863322431713
   PubMedGoogle Scholar
• SenzerNNKaufmanHLAmatrudaTPhase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanomaJ Clin Oncol2009275763577119884534
   PubMed Web of Science ®Google Scholar
• BroyardAIntoxicated by my Illness: and Other Writings on Life and DeathNew York, NYBallantine1992
   Google Scholar
• SpiegelDCancer and depressionBr J Psychiatry Suppl1996301091168864156
   PubMedGoogle Scholar
• BrandbergYMansson-BrahmeERingborgUSjodenPOPsychological reactions in patients with malignant melanomaEur J Cancer199531A21571627718319
   PubMed Web of Science ®Google Scholar
• MissihaSBSolishNFromLCharacterizing anxiety in melanoma patientsJ Cutan Med Surg20037644344815926214
   PubMed Web of Science ®Google Scholar